Status:
UNKNOWN
[18F]Florbetazine ([18F]92) for Beta Amyloid PET Imaging in Alzheimer's Disease
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
40-90 years
Brief Summary
\[18F\]Florbetazine (\[18F\]92) is a molecularly targeted imaging agent for Aβ protein with a novel diaryl-azine scaffold. It has shown specific binding affinity to Aβ aggregates in postmortem human A...
Eligibility Criteria
Inclusion
- Male or Female
- Age ≥ 40 years
- Healthy participants or patients with probable Alzheimer's disease or with dementia due to other causes
Exclusion
- Has allergy to \[18F\]Florbetazine or any of its excipients ;
- Has hypersensitivity to \[11C\]PIB or any of its excipients ;
- Incapable of providing written informed consent or lacking a legally authorized representative (LAR) to provide informed consent ;
- Unwilling or unable to undergo PET scans tracer injections ;
- Unwilling or unable to undergo MRI;
- Any condition that, in the Investigator's opinion, could increase the risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data (e.g., renal or liver failure, advanced cancer);
- Women who are currently pregnant or breastfeeding;
Key Trial Info
Start Date :
January 30 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06141356
Start Date
January 30 2023
End Date
December 31 2025
Last Update
November 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nuclear Medicine, Peking Union Medical College Hopital
Beijing, China, 100730